Abstract

Background: Advanced chronic kidney disease (advanced CKD) patients have several metabolic, immunologic, and hemodynamic derangements that can negatively impact the natural history of cardiac disease. Some efficacious treatments for acute pericarditis such as colchicine and NSAIDS may not be well tolerated by advanced CKD patients. Hypothesis: Advanced CKD may portend worse outcomes based on clinical severity and likely higher side effect of treatments among patients hospitalized with acute pericarditis. Method: A retrospective cohort study with data from the 2016 to 2018 combined National Inpatient Sample (NIS) database was employed. ICD-10 codes were used to sample all adult admissions for acute pericarditis who were dichotomized based on the presence of a secondary diagnosis of advanced CKD including CKD stage 4, stage 5 and dialysis dependent patients. Primary outcomes of study were Mortality rate, length of stay and total hospital charge. Secondary outcomes were cardiac tamponade, cardiogenic shock, pericardial window rate, supraventricular tachycardia (SVT), ventricular tachycardia (VT) and gastrointestinal (GI) bleeding rate. Multivariate linear and logistic regressions were used to adjust for confounders. Results: We identified a total of 36570 admissions for acute pericarditis and among these, 4139.99 representing 5.96% had associated advanced CKD diagnosis. These patients were averagely 5 years older (57.14 vs 52.35, adjusted difference of 4.80 years, 95%CI: 3.11 - 6.48, p-value <0.001) and predominantly female (44.5% vs 39.12%, AOR 1.25, 95%CI: 1.02 - 1.52, p value: 0.029) compared to the counterpart cohort group. Details of study outcomes are summarized in table 1 below. Conclusion: Among patients hospitalized with acute pericarditis, the presence of advanced CKD as a secondary diagnosis was associated with increase length of stay and total charge but without statistical significance effect on odds of mortality and odds of relevant hemodynamic complications.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call